title: Treatment outcomes of pulpotomy in primary molars using two endodontic biomaterials. A 2-year randomised clinical trial.
abstract: OBJECTIVE
  To compare the treatment outcomes of calcium-enriched mixture (CEM) cement and mineral trioxide aggregate (MTA) as pulp dressing biomaterials in vital pulpotomy of carious primary molars.
  
  
  METHODS
  split-mouth randomised clinical trial.
  
  
  METHODS
  Forty children aged 4-8 years with 2 carious teeth requiring pulpotomy were selected and randomly assigned to MTA (n = 40) or CEM (n = 40) groups. After coronal pulp removal, the remaining radicular pulp was covered with an appropriate biomaterial; the teeth were then permanently restored. Clinical/radiographic success/failures were blindly evaluated at 6-, 12- and 24-month follow-ups.
  
  
  METHODS
  the recorded data were analyzed with McNemar test and GEE.
  
  
  RESULTS
  A total of 36, 33 and 35 patients were available for 6-, 12- and 24-month follow-ups, respectively. At the 12-month follow-up only one and three teeth in the CEM and MTA groups had pathologic external root resorption, respectively. The resorbed teeth were then missed due to extraction/exfoliation at the 24-month follow-up; all other treated teeth were sign/symptom-free. Overall, clinical and radiographic outcomes in both MTA/CEM groups were comparable at the three follow-ups without significant differences. Time had no significant effect on the success.
  
  
  CONCLUSIONS
  MTA and CEM demonstrated favourable treatment outcomes for pulpotomy of carious primary molars; CEM may be an effective pulp dressing biomaterial.
authors.affiliation: Dental Research Center, Dental School, Shahid Beheshti Medical University Tehran, Iran.
authors.forename: B
authors.initials: B
authors.lastname: Malekafzali
authors.forename: F
authors.initials: F
authors.lastname: Shekarchi
authors.forename: S
authors.initials: S
authors.lastname: Asgary
mesh_terms: D017607:Aluminum Compounds / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D017610:Calcium Compounds / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003442:Crowns; D003723:Dental Amalgam; D003731:Dental Caries / Q000628:therapy; D003738:Dental Cements / Q000627:therapeutic use; D003785:Dental Pulp Capping / Q000379:methods; D003793:Dental Restoration, Permanent; D003809:Dentin, Secondary / Q000187:drug effects; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008963:Molar / Q000473:pathology; D010087:Oxides / Q000627:therapeutic use; D057872:Pulp Capping and Pulpectomy Agents / Q000627:therapeutic use*; D011672:Pulpotomy / Q000379:methods*; D012391:Root Resorption / Q000209:etiology; D017640:Silicates / Q000627:therapeutic use; D014080:Tooth Exfoliation / Q000503:physiopathology; D014081:Tooth Extraction; D014094:Tooth, Deciduous / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D017607:Aluminum Compounds; D001672:Biocompatible Materials; D017610:Calcium Compounds; D003738:Dental Cements; D004338:Drug Combinations; D010087:Oxides; D057872:Pulp Capping and Pulpectomy Agents; D017640:Silicates; C086631:mineral trioxide aggregate; D003723:Dental Amalgam; D002118:Calcium